Trial · NCT05909826
Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
NCT05909826, Phase 2, Not yet recruiting, Dong-A University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM. Trials, record NCT05909826. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05909826
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Carfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM
- NCT number
- NCT05909826
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 49 participants, estimated
- Lead sponsor
- Dong-A University Hospital
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Interventions
- Carfilzomib, Cyclophosphamide, Dexamethasone
- First posted
- 2023-06-18
- Last updated
- 2023-06-18
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Very good partial response | from the first date of KCd to the day 30 after KCd stop date | Reduction of serum M-protein \> 90% |
| Secondary | Overall response | from the first date of KCd to the day 30 after KCd stop date | sCR+CR+VGPR+PR |
| Secondary | Progression-free survival | from the first date of KCd until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months | the time from the first date of KCd to the date of disease progression or death or censored date |
| Secondary | Overall survival | from the first date of KCd until the date of death from any cause, assessed up to 48 months | the time from the first date of KCd to the date of death or censored date |
| Secondary | Duration of response | from the first date of PR to the date of disease progression or death or censord date, which ever came first, assessed up to 48 months | the time from the first date of PR to the date of disease progression or death or censord date |
| Secondary | Time to response | from the first date of KCd to the date of first date of equal or more than partial response, which ever came first, assessed up to 48 months | the time from the first date of KCd to the first date of partial response |
| Secondary | Safety profile | from the first date of KCd to day 30 after KCd stop date | Adverse events after KCd |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05909826
GET https://conductscience.org/api/trials/v1/NCT05909826/registered